ImmunoCellular Therapeutics Delivers on Key Milestones (OTC:IMUC)

ImmunoCellular just announced their lead monoclonal antibody product candidates ICT-109 had positive result in their lead study of detecting cancerous tissues. The results were statically significant suggesting that this antibody can determine if tissues are cancerous or non-cancerous in plasma and serum study sets.

These results from the study lead IMUC to believe that this ICT-109 molecule can play an important role in early cancer detection which is absolutely critical in for a most efficient treatment.

This will be the second milestone of four that Dr Singh, Ph.D., president and CEO of IMUC, has delivered on time. Singh says IMUC will conduct additional studies testing ICT-109 with other markers to design a robust assay that hopefully will become wildly adopted or the standard in early cancer detection. They will be seeking a partner that specialized in commercial development this type of approach/diagnostic tool.

The next milestone that Dr. Singh is scheduled to deliver on is the Investigational New Drug (IND) filling for their Phase 1 trial on ICT-121. This is a cancer stem cell vaccine that will target will target glioblastoma (brain cancer) as an off the shelf product. This IND filling is expected in the first quarter of 2010. The fourth milestone is the Phase 1 clinical test data for ICT-107. We should most likely expect this data end of 2009 or beginning 2010.

We have many potential good things to come with IMUC and I hope Dr. Sing keeps up his great track record and hits the other two milestones on time.